As we previously reported, last month a Federal Circuit panel affirmed the district court’s judgment that Apotex’s pegfilgrastim and filgrastim biosimilar candidates do not infringe Amgen’s protein refolding method patent.
Amgen’s time for filing a petition for panel rehearing or rehearing en banc of last month’s panel decision expired on December 13, without Amgen filing a petition. Yesterday, the Federal Circuit issued its formal mandate, certifying its judgment in favor of Apotex. Amgen has until February 13, 2018 to file a petition for certiorari with the U.S. Supreme Court. In the absence of a successful certiorari petition, the Federal Circuit’s judgment will mark the final resolution of the case.
The post Federal Circuit Issues Mandate in Amgen v. Apotex appeared first on Big Molecule Watch.